Quick Answer
Contineum Therapeutics, Inc. reported Total Assets of $276.64 million for fiscal year 2025.
Contineum Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $276.64M | +30.0% |
| 2024 | $212.85M | +63.2% |
| 2023 | $130.39M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $190.85M | -11.7% | +4.4% |
| June 30, 2025 | $182.89M | -17.4% | -7.8% |
| March 31, 2025 | $198.26M | +60.5% | -6.9% |
| December 31, 2024 | $212.85M | +63.2% | -1.5% |
| September 30, 2024 | $216.03M | — | -2.4% |
| June 30, 2024 | $221.35M | — | +79.1% |
| March 31, 2024 | $123.56M | — | -5.2% |
| December 31, 2023 | $130.39M | — | — |
- Contineum Therapeutics, Inc. showed an increase of +30.0% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s total assets has grown by 112.2% (from $130.39 million to $276.64 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: